Hypertension in people with diabetes in sub-Saharan Africa: Revealing the hidden face of the iceberg

Diabetes Research and Clinical Practice

Volumn 77, Issue 2, 2007, Pages 293-299

  Choukem, Simeon Pierre ^a   Kengne, Andre Pascal ^b   Dehayem, Yefou Mesmin ^a   Simo, Nenwouo Leonie ^a   Mbanya, Jean Claude ^a  

^a Faculty of Medicine and Biomedical Sciences   (Cameroon)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cameroon; Control; Diabetes; Hypertension; Prevalence

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; AWARENESS; CAMEROON; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DISEASE CONTROL; DISEASE DURATION; FEMALE; HEALTH STATUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL EXAMINATION; POPULATION RESEARCH; PREVALENCE; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; AWARENESS; BLOOD PRESSURE; BODY MASS INDEX; CAMEROON; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; SMOKING;

EID: 34247570852     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.11.007     Document Type: Article

References (41)

1. Mosca L. Epidemiology and prevention of cardiovascular disease. In: Humes H.D. (Ed). Kelley's Textbook of Internal Medicine. fourth ed. (2000), Lippincott Williams and Wilkins, Philadelphia pp.1982-1991
2. International Diabetes Federation, Diabetes and cardiovascular diseases: time to act, Belgium, 2001, pp. 22-50.
3. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
4. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
6. Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 340 (1999) 677-684
7. Curb J.D., Pressel S.L., Cutler J.A., Savage P.J., Applegate W.B., Black H., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. JAMA 276 (1996) 1886-1892
8. Assmann G., and Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and relationship to coronary heart disease. Am. Heart J. 116 (1988) 1713-1724
9. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
10. American Diabetes Association. Treatment of hypertension in adult with diabetes. Diabetes Care 26 (2003) 80-82
11. Sobngwi E., Mbanya J.C., Moukouri E.N., and Ngu K.B. Microalbuminuria and retinopathy in a diabetic population of Cameroon. Diabetes Res. Clin. Pract. 44 (1999) 191-196
12. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., and Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338 (1998) 645-652
13. Tatti P., Pahor M., Byington R.P., Di Maurio P., Guarisco R., Strollo G., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 (1998) 597-603
14. Ibrahim M.M., Rizk H., Appel L.J., AroussyF El W., Helmy S., Sharaf Y., et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Result from the Egyptian national hypertension project (NHP). Hypertension 26 (1995) 886-890
15. Cappuccio F.P., Mica F.B., Emmett L., Kerry S.M., Antwi S., Martin-Peprah R., et al. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension 43 (2004) 1017-1022
16. Epidemiology Group of the Société Française d'Hypertension Artérielle and the IHPAF Working Physicians Group. Prevalence and therapeutic control of hypertension in 30,000 subjects in the workplace. Hypertension 38 (2001) 449-454
17. Wolf-Maier K., Cooper R.S., Kramer H., Banegas J.R., Giampaoli S., Joffres M.R., et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43 (2004) 10-17
18. Colhoun H.M., Dong W., and Poulter N.R. Blood pressure screening, management and control in England: results from the health survey for England 1994. J. Hypertens. 16 (1994) 747-752
19. Tarnow L., Rossing P., Gall M.A., Nielsen F.S., and Parving H.H. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17 (1994) 1247-1251
20. Anonymous, Hypertension in Diabetes Study: I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications, J. Hypertens. 11 (1993) 309-317.
21. Kamadjeu R., Edwards R., Atanga J., Unwin N., Kiawi E., and Mbanya J. Prevalence, awareness and management of hypertension in Cameroon: findings of the 2003 Cameroon burden of diabetes baseline survey. J. Hum. Hypertens. 20 (2006) 91-92
22. Mbanya J.C., Kengne A.P., Choukem S.P., Dehayem M.Y., Simo L., Fezeu L., et al. Prevalence of hypertension and selected cardiovascular risk factors among patients with diabetes in Cameroon. Diabetes Metab. 29 (2003) 4S309 (Abstract)
23. Alberti K.G.M.M., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15 (1998) 539-553
24. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (2003) S33-S50
25. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328 (2004) 634-640
26. Anonymous, The sixth Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI), Arch. Int. Med. 157 (1997) 2413-2446.
27. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (The JNC 7 report). JAMA 289 (2003) 2560-2572
28. Vijan S., and Hayward R.A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann. Intern. Med. 138 (2003) 593-602
29. Otieno C.F., Vaghela V., Mwendwa F.W., Kayima J.K., and Ogola E.N. Cardiovascular risk factors in patients with type 2 diabetes mellitus in Kenya: levels of control attained at the Outpatient Diabetic Clinic of Kenyatta National Hospital, Nairobi. East Afr. Med. J. 82 (2005) S184-S190
30. Maahs D.M., Kinney G.L., Wadwa P., Snell-Bergeon J.K., Dabelea D., Hokanson J., et al. Hypertension prevalence, awareness, treatment, and control in an adult population and a comparable general population. Diabetes Care 28 (2005) 301-306
31. Weerasuriya N., Siribaddana S., Dissanayake A., Subasinghe Z., Wariyapola D., and Fernando D.J.S. Long-term complications in newly diagnosed Sri Lankan patients with type 2 diabetes mellitus. Q. J. Med. 91 (1998) 439-443
32. X. Girerd, G. Amah, Le diabétique vu parle cardiologue. Phase 5, Paris, 2002, pp. 12-19.
33. Shey Wiysonge C.U., Ngu Blackett K., and Mbuagbaw J.N. Risk factors and complications of hypertension in Yaounde, Cameroon. Cardiovasc. J. S. Afr. 15 (2004) 215-219
34. Joffres M.R., Ghadirian P., Fodor J.G., Petrasovits A., Chockalingam A., and Hamet P. Awareness, treatment, and control of hypertension in Canada. Am. J. Hypertens. 10 (1997) 1097-1102
35. Chamontin B., Poggi L., Lang T., Menard J., Chevalier H., Gallois H., et al. Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice. Am. J. Hypertens. 11 (1998) 759-762
36. Cooper R.S., Rotimi C.N., Kaufman J.F., Muna W.F.T., and Mensah G.A. Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy. BMJ 316 (1998) 614-617
37. Okoro E.O., and Oyejola B.A. Inadequate control of blood pressure in Nigerians with diabetes. Ethn. Dis. 14 (2004) 82-86
38. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 351 (1998) 1755-1762
39. UK Prospective Diabetes Study. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 352 (1998) 837-853
40. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N. Engl. J. Med. 342 (2000) 145-154
41. Berlowitz D., Ash A., Hickey E., Glickman M., Friedman R., and Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 26 (2003) 355-359